Tracking Real-Life results for a common eczema medication
NCT ID NCT06353087
Summary
This study aims to observe how patients with moderate-to-severe atopic dermatitis (eczema) respond to the medication abrocitinib in real-world, everyday clinical practice. It will follow 200 patients aged 12 and older who are newly prescribed this medication by their doctor. Researchers will track how well the drug controls symptoms like itching and skin inflammation, and how long patients stay on the treatment, over a 12-month period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang Gung Hospital Linkou
NOT_YET_RECRUITINGTaoyuan District, 333, Taiwan
-
Chang Gung Memorial Hospital at Kaohsiung
RECRUITINGKaohsiung City, 83301, Taiwan
-
Kaohsiung Medical University Hospital
NOT_YET_RECRUITINGKaohsiung City, 807377, Taiwan
-
MacKay Memorial Hospital
NOT_YET_RECRUITINGTaipei, 10449, Taiwan
-
NTUH
RECRUITINGTaipei, 100, Taiwan
-
Taipei Medical University - Shuang Ho Hospital
NOT_YET_RECRUITINGNew Taipei City, 23561, Taiwan
-
Taipei Veterans General Hospital
NOT_YET_RECRUITINGTaipei, 11217, Taiwan
-
Tri-Service General Hospital
NOT_YET_RECRUITINGTaipei, 11490, R.O.C., Taiwan
Conditions
Explore the condition pages connected to this study.